Letter from the CEO
Advicenne was founded in 2007 on the simple premise that if a treatment for a rare kidney disease is a possibility, it should become a reality. Over a decade later, we have made significant headway, commercializing in Europe and expanded our clinical trials to America, with that same commitment still standing at the heart of what we do.
At Advicenne we are entering a period of transformation, which I am very honoured to lead us through, together with a newly established management team, and as we continue our journey to becoming a successful commercial specialty pharmaceutical company.
Sibnayal® (combination of Potassium citrate and Potassium bicarbonate), our lead product was approved in Europe and in the UK in 2021. The next step in our journey to become a mature specialty pharmaceutical company is to make Sibnayal® a commercial success. We already signed partnerships in Europe to expand its availability.
The entire team at Advicenne are very proud to be part of our story so far and look forward to making a real difference in the future.